Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

News Articles

UK: GlaxoSmithKline chief's pay package more than doubles to £6.7m
by Jill TreanorThe Guardian (UK)
March 12th, 2012
GlaxoSmithKline boss Sir Andrew Witty's pay package more than doubled to £6.7m last year – but the drugs group reckons he remains underpaid and has awarded him a new deal which could generate up to £10.4m this year.

INDIA: Controller General Overrules Bayer, Allowing Generic Drug
by Vikas Bajaj and Andrew PollackNew York Times
March 12th, 2012
India’s government authorized a national drug manufacturer to make and sell a generic copy of a patented Bayer drug used to treat advanced kidney cancer and liver cancer, saying that Bayer charged a price that was unaffordable to most of the nation.

INDIA: Supreme Court to Hear Dispute on Drug Patents
by Vikas Bajaj and Andrew PollackNew York Times
March 6th, 2012
A Swiss drug company, Novartis, will go before the Indian Supreme Court this monnth to fight patent laws that protect the global supply of inexpensive medicines to treat AIDS, cancer and other diseases. The lawsuit - which involves a drug called Gleevec - is being opposed by international aid groups.

US: Online Age Quiz Is a Window for Drug Makers
by STEPHANIE CLIFFORDNew York Times
March 25th, 2009
RealAge, promising to help shave years off your age, has become one of the most popular quizzes on the Internet. The test asks 150 questions about lifestyle and family history to assign a “biological age." But then pharmaceutical companies pay RealAge to compile test results of RealAge members and send them marketing messages by e-mail.

US: High Court Eases Way to Liability Lawsuits
by Jess BravinWall Street Journal
March 5th, 2009
The Supreme Court said drug makers can be sued in state court over alleged defects, even if the Food and Drug Administration has approved a medication's use. The 6-3 ruling undercuts years of business efforts to block state suits over the safety of products from motorcycle brakes to railway cars.

SWITZERLAND: Davos Scales Back Glitz
by Associated PressNew York Times
January 25th, 2009
The economic crisis that emerged out the collapse of securities based on shaky U.S. mortgages poses challenges for the Davos World Economic Forum, an arena that has championed market-driven approaches.

US: Research Center Tied to Drug Company
by GARDINER HARRISThe New York Times
November 24th, 2008
Court documents reveal that Dr. Joseph Biederman, a renowned child psychiatrist, pushed Johnson & Johnson to fund a research center whose goal was “to move forward the commercial goals of J&J.”

US: Radio Host Has Drug Company Ties
by GARDINER HARRISThe New York Times
November 21st, 2008
An influential psychiatrist who was the host of the popular NPR program “The Infinite Mind” earned at least $1.3 million from 2000 to 2007 giving marketing lectures for drugmakers, income not mentioned on the program.

US: Eli Lilly settles Zyprexa inquiries in 32 states
by TOM MURPHY and MARLEY SEAMANAssociated Press
October 7th, 2008
Drugmaker Eli Lilly & Co. cleared another legal cloud hanging over its top-selling drug Zyprexa when it announced a $62 million settlement Tuesday, but several other storms are still brewing for the antipsychotic medication.

ARGENTINA: Is GlaxoSmithKline Behaving Badly in Argentina?
by AINA HUNTERABC News
September 23rd, 2008
Michaela, a deceased 5 month old, is one of more than 13,000 Argentine children to participate in a clinical study implemented a little more than a year ago by the London-based GlaxoSmithKline, the world's second-largest drug manufacturer.

US: Judge to Unseal Documents on the Eli Lilly Drug Zyprexa
by MARY WILLIAMS WALSHThe New York Times
September 5th, 2008
A federal judge in Brooklyn decided on Friday to unseal confidential materials about Eli Lilly’s top-selling antipsychotic drug Zyprexa, citing “the health of hundreds of thousands of people” and “fundamental questions” about the way drugs are approved for new uses.

US: U.S. Drug Ads Questioned
by KEITH J. WINSTEIN and SUZANNE VRANICAThe Wall Street Journal
September 3rd, 2008
Consumer advertising for prescription drugs had a negligible impact on sales of products studied by Harvard Medical School researchers -- in a finding that may confound both advertisers and their opponents.

US: For Widely Used Drug, Question of Usefulness Is Still Lingering
by ALEX BERENSONThe New York Times
September 1st, 2008
About the only point on which both sides agree is that no one can judge ezetimibe’s safety and benefits for certain without more data, ideally from a clinical trial covering more than 10,000 patients and lasting several years, long enough to show that the drug actually helps patients live longer or avoid heart attacks.

GLOBAL: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise
by Elisabeth RosenthalThe New York Times
August 19th, 2008
The lightning-fast transition from newly minted vaccine to must-have injection in the United States and Europe represents a triumph of what the manufacturers call education and their critics call marketing.

US: Psychiatric Group Faces Scrutiny Over Drug Industry Ties
by BENEDICT CAREY and GARDINER HARRISThe New York Times
July 12th, 2008
Senator Charles E. Grassley, right, Republican of Iowa, is demanding that the American Psychiatric Association give an accounting of its financing from the pharmaceutical industry.

US: U.S. Probe of Glaxo's Paxil Widens
by ALICIA MUNDYThe Wall Street Journal
June 20th, 2008
A Justice Department investigation of GlaxoSmithKline PLC's handling of its blockbuster antidepressant drug Paxil, including its marketing and safety research, appears to be widening.

US: Mannatech Settles Holder Suits
by SUZANNE SATALINEWall Street Journal
June 13th, 2008
Dietary-supplements maker Mannatech Inc. said it settled several lawsuits with shareholders who accused the company of using improper sales tactics to boost the value of the stock.

US: Researchers Fail to Reveal Full Drug Pay
by GARDINER HARRIS and BENEDICT CAREYThe New York Times
June 8th, 2008
A world-renowned Harvard child psychiatrist whose work has helped fuel an explosion in the use of powerful antipsychotic medicines in children earned at least $1.6 million in consulting fees from drug makers from 2000 to 2007 but for years did not report much of this income to university officials, according to information given Congressional investigators.

US: Walgreen to Pay $35 Million To Settle Drug-Switch Charges
by HEATHER WON TESORIEROWall Street Journal
June 4th, 2008
Walgreen Co. has agreed to pay $35 million to settle allegations that it improperly switched customers to more expensive forms of pills paid for by Medicaid, the government health care program for the poor.

US: Merck Agrees to Settlement Over Vioxx Ads
by THE ASSOCIATED PRESSThe New York Times
May 21st, 2008
The drug maker, Merck & Company, has agreed to pay $58 million as part of a multistate settlement of accusations that its ads for the once-popular painkiller Vioxx deceptively played down the health risks.

Displaying 1-20 of 163  
Next >> 
Last Page » 
« Show Complete List »